Kolexia
Bouabdallah Reda Biologie médicale
Bouabdallah Reda
Biologie médicale
Cabinet libéral
Aix-en-Provence, France
327 Activités
2 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Lymphome B Lymphome B diffus à grandes cellules Lymphome malin non hodgkinien Lymphome folliculaire Récidive tumorale locale Maladie du greffon contre l'hôte Lymphome T

Collaborateurs

Voir plus
Blaise Didier
Blaise Didier
Centre Paoli-Calmettes, Marseille, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France
Furst Sabine
Furst Sabine
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Janssen
13 collaboration(s)
Dernière en 2022
Takeda Pharmaceutical
10 collaboration(s)
Dernière en 2023
Abbvie
6 collaboration(s)
Dernière en 2021
AstraZeneca
6 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma: Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   21 février 2024
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma: A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.
Essai Clinique (Celgene)   05 décembre 2023
R2-CHOP2: A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   04 décembre 2023
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma
Essai Clinique (Celgene)   19 octobre 2023
RELEVANCE: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Essai Clinique (Celgene)   10 août 2023
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Essai Clinique (Karyopharm)   03 août 2023
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Hematology (Amsterdam, Netherlands)   05 mai 2023
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma: A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   16 mars 2023
Co-occurrence of mucosal leishmaniasis caused by Leishmania infantum and mucosal-associated lymphoid tissue lymphoma.
Travel medicine and infectious disease   15 décembre 2022